Published in Am J Surg Pathol on October 01, 2011
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol (2012) 1.45
Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol (2013) 1.23
Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol (2014) 1.11
Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol (2014) 1.08
Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. J Urol (2013) 0.99
Mapping of succinate dehydrogenase losses in 2258 epithelial neoplasms. Appl Immunohistochem Mol Morphol (2014) 0.90
Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review. Int J Biochem Cell Biol (2014) 0.90
Aerobic glycolysis: a novel target in kidney cancer. Expert Rev Anticancer Ther (2013) 0.89
Succinate dehydrogenase expression in breast cancer. Springerplus (2013) 0.86
Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association. Virchows Arch (2015) 0.83
Succinate dehydrogenase deficiency is rare in pituitary adenomas. Am J Surg Pathol (2014) 0.82
Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas. Chin J Cancer Res (2016) 0.81
The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations. Endocrine (2014) 0.80
[Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)]. Pathologe (2015) 0.80
Exploring the association of succinate dehydrogenase complex mutations with lymphoid malignancies. Fam Cancer (2014) 0.78
Succinate dehydrogenase B: a new prognostic biomarker in clear cell renal cell carcinoma. Hum Pathol (2015) 0.77
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat Commun (2016) 0.77
A novel germline mutation in SDHA identified in a rare case of gastrointestinal stromal tumor complicated with renal cell carcinoma. Int J Clin Exp Pathol (2015) 0.77
Syndromic gastrointestinal stromal tumors. Hered Cancer Clin Pract (2016) 0.76
Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Paragangliomas. Head Neck Pathol (2017) 0.75
The ISUP system of staging, grading and classification of renal cell neoplasia. J Kidney Cancer VHL (2014) 0.75
Carney triad, SDH-deficient tumors, and Sdhb+/- mice share abnormal mitochondria. Endocr Relat Cancer (2015) 0.75
[Succinate dehydrogenase (SDH)-deficient renal cell carcinoma]. Pathologe (2016) 0.75
Foamy cell (hibernoma-like) change is a rare histopathological feature in renal cell carcinoma. Virchows Arch (2014) 0.75
Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127). Endocr Pathol (2017) 0.75
[Renal cancer biomarkers. What is justified?]. Pathologe (2012) 0.75
Intensive versus conventional glucose control in critically ill patients. N Engl J Med (2009) 26.30
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Hypoglycemia and risk of death in critically ill patients. N Engl J Med (2012) 6.17
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J (2008) 4.51
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst (2013) 3.06
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85
Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst (2009) 2.56
Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst (2012) 2.44
Role of the WNK-activated SPAK kinase in regulating blood pressure. EMBO Mol Med (2010) 2.36
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol (2013) 2.26
Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol (2012) 2.22
The vitamin D receptor (VDR) is expressed in skeletal muscle of male mice and modulates 25-hydroxyvitamin D (25OHD) uptake in myofibers. Endocrinology (2014) 2.16
Pheochromocytoma: current approaches and future directions. Oncologist (2008) 2.05
Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol (2005) 2.00
A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res (2005) 1.95
Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest (2003) 1.95
Granulomatous interstitial nephritis. Clin J Am Soc Nephrol (2007) 1.92
Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol (2008) 1.73
Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol (2010) 1.73
Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology (2010) 1.65
Bone as a source of FGF23: regulation by phosphate? Bone (2004) 1.63
Abnormal skeletal and cardiac development, cardiomyopathy, muscle atrophy and cataracts in mice with a targeted disruption of the Nov (Ccn3) gene. BMC Dev Biol (2008) 1.62
miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clin Cancer Res (2009) 1.62
Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab (2013) 1.61
Potential pitfalls in the diagnosis of phaeochromocytoma. Med J Aust (2005) 1.61
The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res (2008) 1.58
Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol (2010) 1.56
Immunohistochemistry to detect hereditary nonpolyposis colorectal cancer in young patients: the 7-year Auckland experience. Dis Colon Rectum (2011) 1.55
Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res (2009) 1.53
Expanding indications for recombinant human TSH in thyroid cancer. Thyroid (2008) 1.49
Inappropriate use of antibiotics for acute respiratory tract infections in a rural emergency department. Can J Rural Med (2005) 1.49
Association of the TSHR gene with Graves' disease: the first disease specific locus. Eur J Hum Genet (2005) 1.49
Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas. Clin Endocrinol (Oxf) (2013) 1.46
The roles of vitamin D in skeletal muscle: form, function, and metabolism. Endocr Rev (2012) 1.44
Renal and vascular glutathione S-transferase mu is not affected by pharmacological intervention to reduce systolic blood pressure. J Hypertens (2009) 1.44
Academic health science centres in Australia: let's get competitive. Med J Aust (2011) 1.43
Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol (2006) 1.40
Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer (2009) 1.38
BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery (2010) 1.36
Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol (2010) 1.32
Psychological outcomes and risk perception after genetic testing and counselling in breast cancer: a systematic review. Med J Aust (2003) 1.32
The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell (2013) 1.30
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol (2007) 1.29
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res (2006) 1.27
Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab (2003) 1.22
MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res (2011) 1.22
Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol (2011) 1.19
Phaeochromocytoma: current concepts. Med J Aust (2005) 1.18
BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol (2013) 1.16
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) (2008) 1.15
Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. N Engl J Med (2011) 1.14
Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab (2002) 1.12
MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer (2010) 1.11
Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol (2014) 1.11
Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist (2008) 1.09
Elevated serum FGF23 concentrations in plasma cell dyscrasias. Bone (2006) 1.09
External ophthalmic findings in multiple endocrine neoplasia type 2B. Clin Experiment Ophthalmol (2004) 1.09
Vitamin D signaling regulates proliferation, differentiation, and myotube size in C2C12 skeletal muscle cells. Endocrinology (2013) 1.07
Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology (2007) 1.07